A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05217446 |
|
Recruitment Status :
Recruiting
First Posted : February 1, 2022
Last Update Posted : April 20, 2023
|
Sponsor:
Pfizer
Collaborators:
Merck Sharp & Dohme LLC
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 28, 2026 |
| Estimated Study Completion Date : | March 28, 2027 |